Publications by authors named "H Guillot"
Idiopathic multicentric Castleman disease (iMCD) is a lymphoproliferative disease of unknown etiology. Deciphering mechanisms involved in CD pathogenesis may help improving patients' care. Six cases of stereotyped sub-diaphragmatic iMCD affecting lower limb-draining areas and associated with severe and often ulcerative lower extremity chronic dermatological condition were identified in our cohort.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the diagnosis and treatment outcomes of multidrug-resistant osteoarticular tuberculosis (MDR-OATB) in France, based on a review of 23 cases from 2007 to 2018.
- - Most affected patients were young males, with the spine being the most common site of infection; a significant portion had prior tuberculosis treatments.
- - Despite a high treatment success rate (91%) achieved with a mean regimen of four drugs over approximately 20 months, the ideal treatment protocol for MDR-OATB, including drug combinations and surgical options, is still not established.
Background: Little is known regarding the optimal management of nocardiosis among solid organ transplant (SOT) recipients. It is often suggested to avoid trimethoprim/sulfamethoxazole (TMP-SMX) monotherapy in heavily immunocompromised patients (such as SOT recipients) and/or in case of severe or disseminated nocardiosis. Our aim was to report our experience with TMP-SMX monotherapy in SOT recipients with nocardiosis.
View Article and Find Full Text PDFAbdominal tuberculosis (ATB) is uncommon and not very well known by clinicians. We describe the characteristics, evolution, and treatment of patients with ATB in two large hospitals in the Paris region. We reviewed all records of patients treated for ATB, from January 01, 2010 to December 01, 2016, diagnosed by bacteriological and/or histological methods or highly suspected because of clinical/radiological features.
View Article and Find Full Text PDFArticle Synopsis
- Tocilizumab, an anti-interleukin-6 receptor treatment, showed potential benefits for severe COVID-19 pneumonia when given timely as a single 400 mg dose.
- In a study of 246 patients, those treated with tocilizumab had significantly better outcomes compared to those who did not receive the medication, with a lower rate of mortality and ventilatory support needed.
- The results indicated that tocilizumab could improve survival without the need for mechanical ventilation, making it a promising option for severe COVID-19 patients.